Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04646226 · ClinicalTrials.gov registry record · NA

The Arteriovenous Vascular (AV) ACCESS Trial

A NA study of End-Stage Kidney Disease and Hemodialysis Complication, sponsored by Wake Forest University Health Sciences.

Active
Registry status
NA
Development phase
103
Enrollment target
7
Study locations

NCT04646226: Active NA study of End-Stage Kidney Disease and Hemodialysis Complication, sponsored by Wake Forest University Health Sciences.

NCT04646226 is a NA study of End-Stage Kidney Disease and Hemodialysis Complication that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 103 participants, below the 461-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04646226, a NA study of End-Stage Kidney Disease and Hemodialysis Complication, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
103 participants
Enrollment target
7
Study locations

Study Summary

This study is to prospectively compare the effectiveness and safety of the two types of arteriovenous access placement (fistula or graft) in older adults with end stage kidney disease and multiple chronic conditions

Primary Outcome

Determine the effects of arteriovenous (AV) fistula vs. AV graft vascular access strategy on the rate of catheter-free dialysis days

Interventions

  • DEVICE AV graft
  • PROCEDURE surgical intervention for creation of a fistula

Study Locations (7)

Alabama

  • University of Alabama at Birmingham School of Medicine - Birmingham

California

  • UCLA - Los Angeles

Maryland

  • Johns Hopkins School of Medicine - Baltimore

North Carolina

  • Atrium Wake Forest Baptist Medical Center - Winston-Salem

South Carolina

  • Prisma Health Upstate - Greenville

Tennessee

  • University of Tennessee Medical Center at Knoxville - Knoxville

Wisconsin

  • University of Wisconsin School of Medicine and Public Health - Madison

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2022-08-18
Est. Completion 2027-08-31
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the registry record for NCT04646226 still lists

NCT04646226 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 461-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (78% lower).

The record links to 2 conditions, with End-Stage Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which AV graft is the first listed.

NCT04646226 lists 7 locations in 7 states (Alabama, California, Maryland).

Frequently Asked Questions

What is clinical trial NCT04646226 about?

NCT04646226 is a clinical study titled "The Arteriovenous Vascular (AV) ACCESS Trial". This study is to prospectively compare the effectiveness and safety of the two types of arteriovenous access placement (fistula or graft) in older adults with end stage kidney disease and multiple chronic conditions

What is the current status of trial NCT04646226?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 103 participants. The study started on 2022-08-18. Estimated completion is 2027-08-31.

What conditions does trial NCT04646226 study?

This clinical trial studies the following conditions: End-Stage Kidney Disease, Hemodialysis Complication.

What interventions are being tested in trial NCT04646226?

The interventions under investigation include: AV graft (DEVICE), surgical intervention for creation of a fistula (PROCEDURE).

Who is sponsoring clinical trial NCT04646226?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04646226 being conducted?

This trial has 7 study locations across Alabama, California, Maryland, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End-Stage Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04646226's enrollment target sits among peer trials

103 9th of 20 higher than 11 of 20 other End-Stage Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End-Stage Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04646226, the US trial registry maintained by the National Library of Medicine. NCT04646226 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.